

IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Cancer Biomarkers and Therapy

Guest Editor:

Dr. Michele Ghidini

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

Deadline for manuscript submissions:

closed (25 November 2023)

Message from the Guest Editor

Biomarkers play a crucial role in the diagnosis, treatment, and management of cancer patients. Nowadays, advances in detection technologies allow greater insight into the molecular mechanisms of a variety of malignancies. Additionally, biomarkers are currently in clinical practice with a prognostic role to identify patients' outcome and a predictive role for response to chemotherapy, targeted agents, and immunotherapy.

This Special Issue aims at reviewing the current state of cancer biomarker development and the prospects for improving cancer care with new technologies and biomarkers.







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

Contact Us